ClinicalTrials.gg
CompletedNCT06108362Updated Oct 13, 2026

Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients

A Phase 4 interventional study of Terlipressin and normal saline in Acute Kidney Injury and Liver Transplant; Complications, sponsored by Beijing Tsinghua Chang Gung Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Beijing Tsinghua Chang Gung Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Oct 13, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.

Enrollment
39th of 63
104 · median 152
Started
2023
with 24 others
Phase 4
10 of 168
2 open now
Registered
103rd of 168
by date

Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 39th largest by enrollment of the 63 interventional ones that give a count, is one of 25 that started in 2023, is one of 10 in phase 4, and was the 103rd registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Acute Kidney Injury with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation. Patients were randomly divided into experimental group and control group by numerical randomization table. The experimental group was injected with terlipressin perioperative and the control group was injected with placebo

Read the detailed description

acute kidney injury is a relatively common complication in patients with liver transplantation. Most centers have established prediction models for acute kidney injury after liver transplantation, but the incidence cannot be reduced through perioperative anesthesia management. As an vasopressin receptor agonist, terlipressin can increase blood pressure and improve kidney perfusion at the same time, and perioperative application may reduce the incidence of postoperative acute kidney injury

03

Conditions studied

  • Acute Kidney Injury
  • Liver Transplant; Complications

Browse trials for

Keywords

  • terlipressin
  • Liver Transplant
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 70 years who are scheduled to undergo liver transplantation at our hospital
  • Written provided by the patient or the patient's legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Patients undergoing autologous liver transplantation or combined organ transplantation
  • Patients with lower-extremity arterial stenosis
  • Patients with severe cardiac, pulmonary, or renal disease
  • Patients who received renal replacement therapy before surgery
  • Patients in whom the depth of either kidney from the body surface is greater than 4 cm
  • Patients who received terlipressin within 2 weeks before surgery
  • Patients with a known allergy or to terlipressin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    experimental group

    Continuous terlipressin infusion,Use a syringe to dilute to 50ml Infusion speed is 2ug/kg\*h, From the beginning to the end of the surgery.

    Drug: Terlipressin

  • Placebo comparator
    control group

    Continuous normal saline infusion,Use a syringe to draw 50ml Infusion speed is 4ml/h, From the beginning to the end of the surgery.

    Drug: normal saline

Interventions

  • The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins

    Also known as: Glypressin

  • Drugnormal saline

    The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins

    Also known as: normal sodium

06

What researchers measure

Primary outcomes

  1. Incidence of acute kidney injury after liver transplantation

    acute kidney injury diagnostic criteria (2012 edition)

    Time frame: in 7 days

07

Study locations

1 site
  • Beijing Tsinghua Chang Gung Hospital
    Beijing, Beijing Municipality 1000000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Nov 2024, 12 months.

Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's 12 months is below that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Aug 2023 → Oct 2023, primary completion Jun 2024 → Nov 2024 and completion Jun 2024 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Oct 31, 2023
StartActual
Oct 25, 2023was Aug 2023
Primary completionActual
Nov 8, 2024was Jun 2024
CompletionActual
May 1, 2026was Jun 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Beijing Tsinghua Chang Gung Hospital · Beijing, China
Show 1 removed
  • Beijing Tsinghua Chang Gung Hospital · Beijing, China
Oct 13, 2026
Start date
Aug 18, 2023→Oct 25, 2023
Oct 13, 2026
Primary completion
Jun 30, 2024→Nov 8, 2024 (actual)
Oct 13, 2026
Study completion
Jun 30, 2024→May 1, 2026 (actual)
Oct 13, 2026
Eligibility
2 inclusion criteria added, 1 removed; 7 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • Removed1) Patients who plan to undergo liver transplantation in our hospital 2) Patients or family members sign informed consent
  • AddedPatients aged 18 to 70 years who are scheduled to undergo liver transplantation at our hospital
  • AddedWritten informed consent provided by the patient or the patient's legally authorized representative
Exclusion criteria
  • RemovedPatients <18 years old;② Patients undergoing autologous liver transplantation or combined transplantation;③ Patients with lower extremity artery stenosis;(4) Patients with severe heart disease、lung disease、kidney disease;⑤ Patients with severe lung disease;⑥ Patients who used renal replacement therapy before surgery;⑦ the depth of one kidney from the body surface is greater than 4cm;⑧ Patients treated with terlipressin within 2 weeks before surgery⑨ Patients allergic to terlipressin.
  • AddedPatients undergoing autologous liver transplantation or combined organ transplantation
  • AddedPatients with lower-extremity arterial stenosis
  • AddedPatients with severe cardiac, pulmonary, or renal disease
  • AddedPatients who received renal replacement therapy before surgery
  • AddedPatients in whom the depth of either kidney from the body surface is greater than 4 cm
  • AddedPatients who received terlipressin within 2 weeks before surgery
  • AddedPatients with a known allergy or hypersensitivity to terlipressin
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Beijing Tsinghua Chang Gung Hospital · Beijing, China
    Show 1 removed
    • Beijing Tsinghua Chang Gung Hospital · Beijing, China
    Start date Aug 18, 2023→Oct 25, 2023
    Primary completion Jun 30, 2024→Nov 8, 2024 (now actual)
    Study completion Jun 30, 2024→May 1, 2026 (now actual)
    Eligibility 2 inclusion criteria added, 1 removed; 7 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Removed1) Patients who plan to undergo liver transplantation in our hospital 2) Patients or family members sign informed consent
    • AddedPatients aged 18 to 70 years who are scheduled to undergo liver transplantation at our hospital
    • AddedWritten informed consent provided by the patient or the patient's legally authorized representative
    Exclusion criteria
    • RemovedPatients <18 years old;② Patients undergoing autologous liver transplantation or combined transplantation;③ Patients with lower extremity artery stenosis;(4) Patients with severe heart disease、lung disease、kidney disease;⑤ Patients with severe lung disease;⑥ Patients who used renal replacement therapy before surgery;⑦ the depth of one kidney from the body surface is greater than 4cm;⑧ Patients treated with terlipressin within 2 weeks before surgery⑨ Patients allergic to terlipressin.
    • AddedPatients undergoing autologous liver transplantation or combined organ transplantation
    • AddedPatients with lower-extremity arterial stenosis
    • AddedPatients with severe cardiac, pulmonary, or renal disease
    • AddedPatients who received renal replacement therapy before surgery
    • AddedPatients in whom the depth of either kidney from the body surface is greater than 4 cm
    • AddedPatients who received terlipressin within 2 weeks before surgery
    • AddedPatients with a known allergy or hypersensitivity to terlipressin
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06108362
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Oct 25, 2023
Primary completion
Nov 8, 2024
Completion
May 1, 2026
Last update
Oct 13, 2026

Study contacts

Huan Zhang, Doctor
study chair · department of anesthesia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terlipressin

Start the discussion